Anand Praveen, Privitera Rosario, Donatien Philippe, Misra V Peter, Woods David R
Department of Neurology, Imperial College London, Hammersmith Hospital, London, United Kingdom.
Research and Clinical Innovation, Royal Centre for Defence Medicine, Birmingham, United Kingdom.
Front Neurol. 2021 Aug 19;12:722875. doi: 10.3389/fneur.2021.722875. eCollection 2021.
Neuropathic pain associated with Non-freezing Cold Injury (NFCI) is a major burden to military service personnel. A key feature of NFCI is reduction of the intra-epidermal nerve fibre density in skin biopsies, in keeping with painful neuropathy. Current oral treatments are generally ineffective and have undesirable side effects. Capsaicin 8% patch (Qutenza) has been shown to be well-tolerated and effective for reducing neuropathic pain, for up to 3 months after a single 30-minute application. In this single-centre open label study, 16 military participants with NFCI (mean duration 49 months) received 30-minute Capsaicin 8% patch treatment to the feet and distal calf. Pain symptoms were assessed using a pain diary (with the 11-point Numerical Pain Rating Scale, NPRS) and questionnaires, the investigations included skin biopsies, performed before and three months after treatment. Participants showed significant decrease in spontaneous pain (mean NPRS: -1.1, 95% CI: 0.37 to 1.90; = 0.006), and cold-evoked pain (-1.2, 95% CI: 0.40 to 2.04; = 0.006). The time-course of pain relief over 3 months was similar to other painful neuropathies. Patient Global Impression of Change showed improvement ( = 0.0001). Skin punch biopsies performed 3 months after the patch application showed significant increase of nerve fibres with structural marker PGP9.5 (intra-epidermal nerve fibres [IENFs], < 0.0001; sub-epidermal nerve fibres [SENFs]; =< 0.0001), and of regenerating nerve fibres with their selective marker GAP43 ( = 0.0001). The increase of IENFs correlated with reduction of spontaneous ( = 0.027) and cold-evoked pain ( = 0.019). Capsaicin 8% patch provides an exciting new prospect for treatment of NFCI, with regeneration and restoration of nerve fibres, for the first time, in addition to pain relief.
与非冻伤性冷损伤(NFCI)相关的神经性疼痛是军事人员的一项主要负担。NFCI的一个关键特征是皮肤活检中表皮内神经纤维密度降低,这与疼痛性神经病变相符。目前的口服治疗通常无效且有不良副作用。8%辣椒素贴剂(Qutenza)已被证明耐受性良好,且在单次30分钟应用后长达3个月内对减轻神经性疼痛有效。在这项单中心开放标签研究中,16名患有NFCI的军事参与者(平均病程49个月)接受了针对足部和小腿远端的30分钟8%辣椒素贴剂治疗。使用疼痛日记(采用11点数字疼痛评分量表,NPRS)和问卷对疼痛症状进行评估,调查包括在治疗前和治疗后三个月进行的皮肤活检。参与者的自发疼痛显著减轻(平均NPRS:-1.1,95%CI:0.37至1.90;P = 0.006),冷诱发疼痛也显著减轻(-1.2,95%CI:0.40至2.04;P = 0.006)。3个月内疼痛缓解的时间进程与其他疼痛性神经病变相似。患者总体改善印象显示有改善(P = 0.0001)。贴剂应用三个月后进行的皮肤打孔活检显示,具有结构标记物PGP9.5的神经纤维显著增加(表皮内神经纤维[IENFs],P < 0.0001;皮下神经纤维[SENFs];P =< 0.0001),以及具有其选择性标记物GAP43的再生神经纤维显著增加(P = 0.0001)。IENFs的增加与自发疼痛的减轻(P = 0.027)和冷诱发疼痛的减轻(P = 0.019)相关。8%辣椒素贴剂为NFCI的治疗提供了一个令人兴奋的新前景,除了缓解疼痛外,还首次实现了神经纤维的再生和恢复。